Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – Analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Monopar Therapeutics in a report released on Tuesday, June 24th. Chardan Capital analyst K. Nakae forecasts that the company will earn ($2.02) per share for the year. Chardan Capital has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Chardan Capital also issued estimates for Monopar Therapeutics’ FY2026 earnings at ($2.87) EPS.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.27.
Check Out Our Latest Analysis on MNPR
Monopar Therapeutics Price Performance
Shares of MNPR stock opened at $33.60 on Friday. The firm has a market capitalization of $205.63 million, a PE ratio of -9.66 and a beta of 0.99. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30. The business’s fifty day moving average price is $36.75 and its 200 day moving average price is $34.83.
Insider Transactions at Monopar Therapeutics
In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the transaction, the insider now directly owns 822,255 shares in the company, valued at $28,778,925. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 20.50% of the company’s stock.
Institutional Investors Weigh In On Monopar Therapeutics
Several hedge funds have recently modified their holdings of MNPR. JPMorgan Chase & Co. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $45,000. Geode Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after buying an additional 24,530 shares during the period. ADAR1 Capital Management LLC purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $2,861,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $13,182,000. Finally, RA Capital Management L.P. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $11,247,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Further Reading
- Five stocks we like better than Monopar Therapeutics
- What is Short Interest? How to Use It
- Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making?
- Stock Splits, Do They Really Impact Investors?
- Value Alert: 3 High-Yield Stocks Trading at 52-Week Lows
- Where Do I Find 52-Week Highs and Lows?
- Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.